With an expert team with more than 150 years combined clinical experience, iuvo shares your vision to develop new modalities and therapeutics for the treatment or management of ocular conditions.
Charles Slonim, MD
Chief Medical Officer
Dr. Charles B. Slonim most recently served as an Adjunct Professor of Ophthalmology and Affiliate Professor of Surgery, Division of Plastic Surgery at the University of South Florida College of Medicine in Tampa and Associate Clinical Professor of Ophthalmology at the University of Florida College of Medicine in Gainesville, Florida.
Dr. Slonim teaches physicians about oculoplastic diseases, diagnoses, and surgeries, as well as contact lens technology. He has lectured extensively to ophthalmologists, optometrists and other physicians throughout the United States, and in more than 55 international cities in more than 34 countries around the world. He served as a Consultant at the Olympic Vision Center in the Olympic Village during the 1992 Summer Olympics in Barcelona. He has been a world-renowned Consultant for a number of major contact lens and ophthalmic pharmaceutical companies. He served as a Member for Scientific Advisory Board of Sirion Therapeutics, Inc. and Sirion Holdings Inc. He is the team Ophthalmologist for many Tampa Bay area professional and intercollegiate sports teams, including the Tampa Bay Lightning of the National Hockey League and the University of South Florida intercollegiate sports programs. He has published one book, Eye Was There: A Patient Guide to Coping with the Loss of an Eye, more than 36 scientific journal articles, 20 ophthalmic book chapters, and 11 clinical symposia.
Dr. Slonim is a graduate of Johns Hopkins University and New York Medical College and completed Internship in Ophthalmology from Mt. Sinai Medical Center in Cleveland and Residency in Ophthalmology from Mt. Sinai Medical Center in Cleveland.
Director of Clinical Operations
Roselyn Judd has over 30 years of experience in ophthalmology and 25 years of experience in clinical research. She has been responsible for managing clinical trials for CROs, Pharmaceutical companies and academic institutions. Prior to joining Oculos, Roz was a Global Clinical Site Developer for Alcon, Clinical Trials Manager at Vanderbilt University and the Director of Clinical Operations at Sirion Therapeutics. In her current position, Roz is responsible for the overall study and resource management for Oculos.
Roz has her Bachelor of Science degree in Human Resource Development from Oakland University in Rochester, Michigan.
Associate Director, Clinical Technology
Ms. Cardosa has 13 years of clinical research experience and joined Oculos in January 2013. She has worked on pediatric and adult studies with indications of Dry Eye, Glaucoma, Post-Op Inflammation, Uveitis, ARMD, Amblyopia, Nasolacrimal Duct Obstruction, Esotropia, Leukemia and Lymphoma. Esmeralda has experience with case report form creation, remote electronic data monitoring, on-site monitoring, data verification and coding, site selection, maintenance regulatory files, study start up, investigator meeting preparations and managing central monitoring. She has earned her CCRP certification through SOCRA and is currently in the process of obtaining her Bachelor of Science Degree from the University of Central Florida.
President and CEO
Prior to co-founding iuvo BioScience and taking on the roles of President and CEO, Ben was Vice President of Quality for the Pharmaceutical, Solutions and External Manufacturing organizations of Valeant Pharmaceuticals. Prior to the acquisition of Bausch + Lomb by Valeant, Ben served as Global VP of Quality for the Pharmaceutical Business Unit, and was a member of the B+L Global Leadership Team.
Earlier in his career, he held the position of Director, Quality and Technical Services for Norwich Pharmaceuticals (a contract manufacturing and development organization), responsible for driving new business development and revenue and leading the technical services organization (project managers, engineers, formulators, method developers, etc.) in delivering customer projects, as well as heading up the site quality organization. Ben began his career with Procter & Gamble Pharmaceuticals as a Process Engineer, moving up to roles of increasing responsibility in Product Development, OTC Engineering (Cayey, PR) and Global Clinical Supplies.
Ben holds a BS from Carnegie Mellon University with a double major in Chemical Engineering and Biomedical Engineering, and a dual MS/MAT in Chemistry and Education from Binghamton University.
Mary Richardson, PhD, DABT
Chief Scientific Officer, Executive Vice President
As Chief Scientific Officer at iuvo and one of the company’s co-founders, Mary heads up the Research and Development team. Most recently Mary served as Executive Director of Preclinical Development at Bausch + Lomb, continuing in that role when Valeant Pharmaceuticals purchased the company. Previously, she had been Director of Nonclinical Safety.
Her extensive background includes in-depth research and development experience covering the full range of the preclinical product life cycle. This includes discovery, product development, and post-market support in areas including life cycle management, geo-expansion, and manufacturing. She brings exhaustive knowledge of global regulations and standards for registration of pharmaceutical and medical device products.
Her technical leadership and expertise in drug development of small molecules, peptides, and medical devices has resulted in regulatory approval and success of numerous NDAs, INDs, IMPDs, and 510(k) submissions. She’s an in-demand speaker with many published articles in scientific journals.
Mary earned her PhD from the University of Rochester School of Medicine and Dentistry and is a highly experienced board-certified toxicologist (Diplomate of American Board of Toxicology – DABT) with broad-based technical skills in pharmaceuticals, OTC, medical devices, drug metabolism, toxicology, pharmacokinetics, and pharmacology.
Kathleen Krenzer, OD, PhD, DABT
Research Fellow - Toxicology
Dr. Kathleen Krenzer is a board-certified toxicologist (DABT) serving as a Research Fellow in toxicology, with a focus on ophthalmic product development. Prior to joining iuvo, Kathleen was a Senior Principal Scientist at Bausch + Lomb in the non-clinical safety group.
Kathleen’s expertise in nonclinical product development stems from her previous experiences as a Study Director at a contract research laboratory, overseeing both pharmaceutical and medical device testing, and as a principal/senior principal scientist at Bausch + Lomb where she covered both pharmaceutical and medical device development programs, including 510(k), PMA, IND, and NDA submissions, geo-expansion activities, as well as nonclinical support for marketed products.
As a clinician-scientist, Kathleen brings a wealth of expertise in the area of ophthalmic product development, always maintaining focus on the ultimate beneficiary, the patient. Her background in ophthalmic development includes early discovery with testing in efficacy models through clinical evaluations, having served as part of clinical investigative teams for numerous ophthalmic products.
Kathleen received her BS in Biology from the University of Notre Dame. She earned her Doctor of Optometry degree (OD) from the New England College of Optometry, where she continues to serve as an adjunct professor, teaching in the College’s international programs. She earned her PhD from Boston University School of Medicine in Pathology, focusing on ocular pathology and dry eye disease, and continued her post-doctoral training at the Schepens Eye Research Institute of Harvard University.
Business Development Executive
Ronil currently serves as the Business Development Executive for Oculos Development Services. Prior to that he served as the Director of Business Development and Project Management for Point Guard Partners and its subsidiaries – Oculos Clinical Research and OSD Innovations. He also serves as project lead for several projects leading to NDA submission. Ronil’s duties in his current role involve responding to RFPs, clinical trial budgeting, submitting proposals, soliciting bids from potential vendors, licensing technologies, clinical protocol development, and managing client relations. Prior to joining Point Guard Partners, Ronil worked in research and development labs in the area of drug discovery & drug delivery. His research has been published in peer-reviewed journals. He has vast knowledge and hands-on expertise in molecular biology, biochemistry and animal models for drug discovery and delivery. He has a thorough understanding of signal transduction pathways and has managed several projects involving development of small molecule inhibitors for Rho‑kinase, Proteasome, JAK, Akt, Stat3 and Aurora kinase. Ronil has a Master of Technology and a Master of Science degree in Biotechnology.